Roflumilast transforme Semaglutide en outil de perte de poids à long terme

Roflumilast, a PDE4 inhibitor, can keep cAMP elevated in area postrema neurons for longer, extending semaglutide’s appetite‑suppressing effect.

Heterogeneous cAMP Responses

NIH scientists used a fluorescence imaging technique on live mouse brain slices to watch how semaglutide raised intracellular cAMP in GLP‑1 receptor‑expressing neurons. They found that the response was not uniform: some cells maintained high cAMP levels, while others only showed a brief spike before dropping back to baseline. The transient responders likely internalized or degraded their GLP‑1 receptors, a process that limits the drug’s duration of action.

PDE4 Inhibition Extends Signaling

When the researchers added roflumilast, an FDA‑approved PDE4 inhibitor that blocks cAMP degradation, the transient responders shifted to sustained cAMP elevation. This suggests that PDE4 activity is a bottleneck in the signaling cascade that drives weight loss. By keeping cAMP high, roflumilast could extend the period during which semaglutide suppresses appetite, potentially allowing for less frequent dosing and helping patients who hit a weight‑loss plateau.

Clinical Implications

The study, published in Nature Metabolism (2026) and cited by DOI https://www.nature.com/articles/s42255-026-01534-8, underscores the importance of intracellular signaling in GLP‑1 therapy. If PDE4 inhibition can be safely paired with GLP‑1 agonists, it may open a new class of combination drugs for obesity. Future work will extend imaging to days and weeks and test the combination in human trials.

The next step is to evaluate safety and efficacy in clinical settings, but the data already point to a promising strategy for enhancing the durability of GLP‑1‑based weight‑loss treatments.

Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov